An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies.

person Stephen Anthony Strickland SCRI at TriStar Centennial, Nashville, TN info_outline Stephen Anthony Strickland, Emily K. Curran, Omer Hassan Jamy, Mary-Elizabeth Percival, Amy J. Johnson, Joseph Birkett, Xin Huang, Melanie M. Frigault, Hans-georg Lerchen, Beatrix Stelte-Ludwig, Tasheda Navarro, Jim Peck, Wyatt Gross, Raquel Izumi, Ahmed M. Hamdy, Naval Guastad Daver

Authors person Stephen Anthony Strickland SCRI at TriStar Centennial, Nashville, TN info_outline Stephen Anthony Strickland, Emily K. Curran, Omer Hassan Jamy, Mary-Elizabeth Percival, Amy J. Johnson, Joseph Birkett, Xin Huang, Melanie M. Frigault, Hans-georg Lerchen, Beatrix Stelte-Ludwig, Tasheda Navarro, Jim Peck, Wyatt Gross, Raquel Izumi, Ahmed M. Hamdy, Naval Guastad Daver Organizations SCRI at TriStar Centennial, Nashville, TN, University of Cincinnati, Cincinnati, OH, University of Alabama at Birmingham, Birmingham, AL, Fred Hutchinson Cancer Center, Seattle, WA, Vincerx Pharma, Palo Alto, CA, Vincerx Pharma, Monheim, Germany, The University of Texas MD Anderson Cancer Institute, Houston, TX Abstract Disclosures Research Funding Vincerx Pharma Background: VIP943 is an anti-CD123 antibody-drug conjugate (ADC) with a unique linker cleaved only by legumain and a novel kinesin spindle protein inhibitor payload. The linker-payload was engineered to increase the therapeutic index thereby improving efficacy and reducing severe toxicities compared with current ADCs. In an in vivo MOLM-13 model, VIP943 had statistically significant (p <0.001) improvement in tumor growth inhibition compared with the only ADC approved for the treatment of acute myeloid leukemia (AML), gemtuzumab ozogamicin (GO). In a nonhuman primate (NHP) single dose toxicology study, VIP943 (20 mg/kg) showed no signs of toxicity as measured by hematology, serum chemistry and survival. In contrast, NHP treated with a single dose of GO (3 mg/kg) had significant toxicity including death and mandatory euthanasia. The single-dose toxicity of GO was ameliorated by substituting the VIP943 proprietary linker and payload on an anti-CD33 antibody (3 mg/kg) as measured by hematology, serum chemistry and survival. (1,2). Methods: This trial in progress (NCT06034275) is an open-label, multicenter, Phase 1, first-in-human (FIH), dose-escalation and dose-optimization study of VIP943 in subjects with relapsed or refractory CD123+ hematologic malignancies including AML, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia. A cycle of VIP943 treatment is 28 days of once weekly intravenous infusions with no pause between cycles. The dose-escalation portion of this study follows a standard 3+3 design. Dose escalation decisions will be made by the safety review committee, and decisions will be based on the incidence of dose-limiting toxicities (DLTs). Based on FDA guidance, a dose-optimization portion of this study will randomize subjects into ≥2 dose cohorts to derive a recommended dose range for Phase 2. The study will also characterize the pharmacokinetics of VIP943 and its components and explore potential biologic activity by assessing pharmacodynamic/exploratory biomarkers, and antitumor activity using standard response criteria. As this is a FIH study, only subjects with CD123+ hematologic malignancies who have exhausted all available therapies or are not fit for standard of care can be enrolled. The results from this study will form the basis for decisions for future studies. Enrollment for cohorts 1 (no DLTs) and 2 (safety review ongoing) has completed. 1. Stelte-Ludwig et al ASH 2022. 2. Stelte-Ludwig et al ASH 2023. Clinical trial information: NCT06034275.

Clinical